Spots Global Cancer Trial Database for Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.

Official Title: Real-world Experience of Immunotherapy Plus Chemotherapy as First-line Treatment With or Without Radiotherapy for Patients With Advanced Oesophageal Squamous Cell Carcinoma in China

Study ID: NCT06190652

Conditions

Metastatic Esophageal Squamous Cell Carcinoma

Interventions

Chemotherapy combined with immunotherapy

radiotherapy

Study Description

Brief Summary: This study is a multi-center, non-interventional study. Clinicopathologic, treatment , outcome and efficacy data will be collected from medical records in metastatic esophageal squamous cell carcinoma (ESCC) patients.

Detailed Description: This study is a multi-center, non-interventional study. Patients' background, treatment pattern, treatment outcome, efficacy will be collected in metastatic esophageal squamous cell carcinoma (ESCC) patients who were treated with chemotherapy combined with immunotherapy as 1st line treatment at approximately 5 institutions. The patients should have received at least 1 cycle of immunotherapy and chemotherapy with or without radiotherapy. Based on these data, overall survival (OS), progression free survival (PFS) from start of 1st line treatment and the role and efficacy of radiotherapy for these patients will be assessed.